ABSTRAcr To determine whether the endogenous opioid peptides play a part in the pathogenesis of asthmatic morning dipping, six patients with chronic asthma with a reproducible peak flow pattern of morning dipping were investigated in a double blind, randomised, crossover study of naloxone versus placebo. Naloxone was given as a loading dose of 8 mg followed by a continuous infusion of 5-6 mg/h from midnight until 10 am on two consecutive nights. Naxolone had no significant effect on PEFR, FEV,, or FVC at 6 am. There was, however, an improvement over placebo values in all these indices between the hours of 8 am and 8 pm on the day after the first naloxone infusion in all six patients. This effect was not observed after the second naloxone infusion.
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There are many asthmatic patients whose "morning dipping" of lung function is refractory to treatment with bronchodilators and steroids. These patients constitute an important clinical problem in view of their susceptibility to severe and sometimes fatal airways obstruction during the sleeping hours. The aetiology of morning dipping, however, remains poorly understood.
There have been suggestions that the endogenous opioids may be concerned in the induction of airways obstruction in certain patients. The administration of chlorpropamide and alcohol to some diabetic patients may induce airways obstruction,' which is attenuated by the prior administration of the specific opiate antagonist naloxone.2 Infusion of the enkephalin analogue desamino metenkephalin (DAMME; Sandoz) in one patient was followed by an asthmatic attack. Each patient was studied for 14 days, starting with a four day control period (fig 1) . On the fourth night an intravenous infusion of either naloxone or placebo (naloxone vehicle provided by the manufacturers) was given from midnight until 10 am and the same infusion was repeated the following night. A three day recovery period followed and the other infusion was given on the ninth and tenth nights in the same manner as above, followed by a second recovery period. The order in which the two active and two placebo infusions were given was randomised and carried out under double blind conditions. The infusion order was placebo followed by naloxone in three patients and naloxone followed by placebo in the other three. Naloxone 8 mg was given as a loading dose over 20 minutes intravenously followed by 56 mg made up to 500 ml with normal saline, infused at a constant rate of 5*6 mg per hour. Table 2 shows that there was no significant improvement over the placebo period in the 6 am PEFR, FEV,, or FVC measurements while the patients were having naloxone. Similarly, there was no significant difference between the 6 am measurements in the periods of recovery from naloxone and from placebo. The spirometric data obtained from patient 6 at times other than 6 am were incomplete so they were excluded from further analysis. Figure 2 shows that there was a small improvement over the placebo period in all three indices of lung function between 8 am and 8 pm after the first naloxone infusion. These results were significant for PEFR at 2 pm (37%, p < 0-02 by the paired t test) and for FEV, at 2 pm (13%, p < 0.02) and 4 pm (29%, p < 0.05). At these times the improvement was seen in all five patients. The mean maximum improvement in FVC was observed at 4 pm (22%) but did not reach significance (p > 0.1). The differences in lung function between the naloxone and placebo periods were observed only after the first infusion. The significant differences persisted, however, when the means of the first and second infusions were examined.
Patient 6 followed the same trend as the other five patients, with an improvement in all indices between 4 pm and 10 pm after naloxone compared with placebo.
The only adverse effect we encountered was in patient 2, who experienced an episode of shivering resembling a rigor. This started at 7.30 am during al-Damluji, Thompson, Citron, Turner-Warwick the second naloxone infusion and ceased 15 minutes after the infusion was terminated, only to recur for five minutes several hours later. During these episodes the patient was afebrile and had no other abnormal signs. She had not experienced any adverse effect during the first naloxone infusion. Shivering after administration of naloxone has previously been described.5 There were no other effects which could have enabled the patients to distinguish between naloxone and placebo. All patients slept well during the nights when they had the infusions and there was no difference in their assessment of sleep quality between the naloxone and the placebo nights, which is in agreement with previous observations.6 Discussion Although circadian rhythms of PEFR are observed in normal individuals,' the mechanism whereby this phenomenon is exaggerated in asthmatic patients is unclear. Sleep studies have shown no significant differences in the electroencephalographic stages between asthmatic and normal subjects, and there is no association of attacks of nocturnal asthma with any particular sleep stage.8 Furthermore, most subjects still show dips in the morning if their sleep is disrupted,9 suggesting that morning dipping is not caused by sleep per se. Hypothalamo-pituitaryadrenal function is normal in asthmatic patients'0 I and infusions of hydrocortisone to abolish the circadian rhythm of plasma cortisol do not abolish the circadian pattern of PEFR. '2 Although there is a temporal relationship between the nadirs of PEFR and urinary'3 and plasma '4 catecholamine concentrations, nocturnal administration of salbutamol does not abolish the morning dip in PEFR.'5 The PEFR response to adrenaline is similar at 4 am and 4 pm, suggesting that adrenoceptor dysfunction is not relevant. '6 There is apparently no relationship between morning dipping and house dust allergy," nor does the exaggerated dip seem attributable to the recumbent posture.'8 Differences in drug pharmacokinetics between day and night have been suggested, '9 but this idea needs further investigation.
The apparent lack of progress in understanding the aetiology of the asthmatic morning dip and the suggestion that the endogenous opioids might play a part in airways obstruction prompted us to investigate the role of these peptides in the mediation of the morning dip, using an opiate antagonist.
This study provides no support for the hypothesis that the opioid peptides are mediators of morning dipping as there was no improvement in lung function at 6 am on the mornings of naloxone infusion over placebo mornings. Although opioid receptors have been described with a low affinity for naloxone,20 this is unlikely to explain our inability to show an effect on the morning dip as the dose of naloxone used (a total of 64 mg per patient) was many times larger than the dose used clinically to block the effects of exogenous opiates (0.4-0.8 mg). Weinberger and colleagues2' recently found that naloxone does not inhibit the asthmatic reaction caused by cold air inhalation. They concluded that the endogenous opioid peptides were not concerned in the mediation of airways obstruction in their experimental model, which is in accordance with our results. The small improvement in lung function between 8 am and 8 pm on the first day after naloxone infusion was unexpected. The improvements were significant for PEFR and FEV, but not FVC, presumably because of the small number of patients studied. As the infusions started at midnight and terminated at 10 am, the absence of an effect at 6 am suggests a delayed effect of naloxone on lung function. The mechanism is unclear: naloxone has been shown to increase circulating adrenocorticotrophic hormone (ACTH) and cortisol in normal man22 but four of our patients were taking large doses of prednisolone, which was presumably suppressing their hypothalamo-pituitary-adrenal axes; so an effect of naloxone on ACTH secretion in these circumstances seems unlikely.
No explanation can be offered for the lack of improvement in lung function after the second naloxone infusion, but it is tempting to speculate that naloxone increases f-endorphin secretion by interrupting a negative feedback loop and the resulting delayed high opioid levels may account for the diminished naloxone effect on the second infusion day.
The timing of the infusions was designed to cause the least interruption to the patients' sleep and to answer the question: does naloxone infused overnight abolish asthmatic morning dipping? We believe this study has provided a clear answer to this question in that there was no improvement in lung function at 6 am during naloxone infusion compared with placebo. The small delayed effect of naloxone on lung function is unexplained and requires confirmation and further study.
We thank Professor GM Besser and Dr A Grossman for discussing the study, Endolaboratories for supplying naloxone and placebo, MH Stokoe and T Root for pharmaceutical help, Miss Dawn Beaumont for computing, and our consultant colleagues for allowing us to study their patients. rhythms in lung function. Correspondence Purulent pericarditis with tamponade: a rare complication of pectus repair SIR,-Since the introduction of antibiotics purulent pericarditis has become uncommon and most cases occur after cardiac surgery. However, we have recently encountered such a case following surgery for pectus excavatum. A 22 year old woman developed bilateral pleural effusions one month after classical repair of severe asymmetrical pectus excavatum. She also presented with clinical features of a right calf vein thrombosis. She was anticoagulated with heparin, but sustained a cardiorespiratory arrest 45 days after operation and was thought to have sustained a massive pulmonary embolism. When the chest was opened, however, the pericardium was found to contain a tense collection of pus. This was drained, with immediate improvement in the circulation. Her subsequent postoperative course was uneventful.
Effect of naloxone on circadian
Occasional reports of purulent pericarditis following oesophageal perforation have appeared' and on one occasion this presented as pericardial tamponade.2 Purulent pericarditis rarely occurs after surgery when the pericardium is not opened3 and to our knowledge this is the first report of pyogenic tamponade complicating repair of pectus excavatum.
